A Phase 3 interventional study of NP101 in Migraine Disorders, sponsored by NuPathe Inc.. Completed at 34 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-02-04.
Sponsored by NuPathe Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Migraine Disorders by Teva Pharmaceutical Industries, Ltd. — none open to participants now, none under way, none of them phase 3. Migraine Disorders · Teva Pharmaceutical Industries, Ltd..
Among the 20 studies in Migraine Disorders by Teva Pharmaceutical Industries, Ltd., this one is the 15th largest by enrollment of the 19 interventional ones that give a count, is one of 4 that started in 2009, is one of 12 in phase 3, and was the 6th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →None of the 20 studies in Migraine Disorders by Teva Pharmaceutical Industries, Ltd. is open now. The open studies under Migraine Disorders, anywhere →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 4 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 198 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 353 across the 19 interventional studies. Of the 19 that completed or were terminated, 15 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under NuPathe Inc., one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
NuPathe Inc. is the lead sponsor of 8 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 20 studies in Migraine Disorders by Teva Pharmaceutical Industries, Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective is to evaluate the safety of long-term treatment with NP101 as assessed by:
The secondary objective is to evaluate the long term efficacy of NP101 as assessed by:
This study will use an open-label design to assess the long term safety of NP101 (sumatriptan iontophoretic transdermal patch).
Subjects who continue to be in good health (use of a triptan or use of an NP101 patch is not contraindicated) and received treatment (patch activation) with the study patch for a qualifying migraine under study NP101-007 will be considered eligible for enrollment into the open-label study. Subjects will be expected to remain in the study for up to 12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
sumatriptan iontophoretic transdermal patch
Drug: NP101
Drug pages: Nigella sativa oil · Black Seed Oil Extract Supplement · Sumatriptan
NP101 study patch 4 hour application
Subject Self-examination of Skin Irritation
For each patch application, subjects performed a self-examination of skin irritation using a 5-point scale (0=no redness; 1=minimal skin redness; 2=moderate skin redness with sharp borders; 3=intense skin redness with or without swelling; 4=intense skin redness with blisters or broken skin).
Time frame: 24 hours post patch activation
Pain Relief
Headache pain relief (no pain or mild headache pain) at two hours post activation of NP101.
Time frame: 2 hours
Nausea Free
Nausea free at two hours after patch activation.
Time frame: 2 hours
Phonophobia Free
Phonophobia free at two hours after patch activation.
Time frame: 2 hours
Photophobia Free
Photophobia free at two hours after patch activation.
Time frame: 2 hours
The study was initiated January 2009 and completed in September 2010. Patients were enrolled from 34 investigative sites across the United States.
| Milestone | NP101 |
|---|---|
| Started | 198 |
| Completed | 65 |
| Not completed | 133 |
| Withdrew: Enrolled, not treated | 15 |
| Withdrew: Lost to follow-up | 17 |
| Withdrew: Adverse event | 25 |
| Withdrew: Withdrawal by subject | 52 |
| Withdrew: Protocol violation | 10 |
| Withdrew: Did not apply 6 patches in 1st 3 mths | 14 |
Headache pain relief (no pain or mild headache pain) at two hours post activation of NP101.
| participants | NP101 |
|---|---|
| Pain Relief | 105 ± 0.341 |
For each patch application, subjects performed a self-examination of skin irritation using a 5-point scale (0=no redness; 1=minimal skin redness; 2=moderate skin redness with sharp borders; 3=intense skin redness with or without swelling; 4=intense skin redness with blisters or broken skin).
| scores on a scale | NP101 |
|---|---|
| Subject Self-examination of Skin Irritation | 1.0 ± 0.96 |
Nausea free at two hours after patch activation.
| participants | NP101 |
|---|---|
| Nausea Free | 143 |
Phonophobia free at two hours after patch activation.
| participants | NP101 |
|---|---|
| Phonophobia Free | 109 |
Photophobia free at two hours after patch activation.
| participant | NP101 |
|---|---|
| Photophobia Free | 97 |
Collected over All adverse events were collected from study enrollment until 30 days after the last patch application.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NP101 | — | 2/183 (1.1%) | 66/183 (36.1%) |
| Event | NP101 |
|---|---|
| VertigoEar and labyrinth disorders | 1/183 |
| DehydrationMetabolism and nutrition disorders | 1/183 |
| Event | NP101 |
|---|---|
| Application site pruritusGeneral disorders | 40/183 |
| Application Site PainGeneral disorders | 39/183 |
| Application site hypersensitivityGeneral disorders | 11/183 |
Per protocol, the intent-to-treat (ITT) population was defined as all subjects who applied and activated at least one NP101 study patch and had at least one post baseline assessment for each migraine symptom (pain, photophobia, phonophobia, and nausea). Of the 183 subjects who applied at least one study patch, 181 subjects met the ITT criteria.
| Age, Categorical(Participants) | NP101 |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 183 |
| >=65 years | 0 |
| Age, Continuous(years) | NP101 |
|---|---|
| Mean | 42.0 ± 10.28 |
| Sex: Female, Male(Participants) | NP101 |
|---|---|
| Female | 152 |
| Male | 31 |
| Region of Enrollment(participants) | NP101 |
|---|---|
| United States | 183 |
The record gives a start of Jan 2009, a primary completion of Sep 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.
Results were first posted in May 2013, 2 years 8 months after primary completion. A results delay was requested in Nov 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nigella sativa oil · Black Seed Oil Extract Supplement · Sumatriptan